Martin & Co. Inc. TN Grows Position in Health Catalyst, Inc. (NASDAQ:HCAT)

Martin & Co. Inc. TN grew its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 80.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 490,998 shares of the company's stock after purchasing an additional 218,293 shares during the quarter. Martin & Co. Inc. TN owned approximately 0.81% of Health Catalyst worth $3,471,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of HCAT. The Manufacturers Life Insurance Company grew its position in Health Catalyst by 10.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,162 shares of the company's stock worth $148,000 after acquiring an additional 2,164 shares during the last quarter. Creative Planning lifted its holdings in Health Catalyst by 13.2% in the 3rd quarter. Creative Planning now owns 21,348 shares of the company's stock worth $174,000 after buying an additional 2,486 shares during the period. nVerses Capital LLC purchased a new stake in Health Catalyst in the 3rd quarter worth approximately $59,000. Nepsis Inc. lifted its holdings in Health Catalyst by 67.9% in the 3rd quarter. Nepsis Inc. now owns 2,104,528 shares of the company's stock worth $17,131,000 after buying an additional 851,448 shares during the period. Finally, Janney Montgomery Scott LLC purchased a new stake in Health Catalyst in the 3rd quarter worth approximately $897,000. 85.00% of the stock is currently owned by institutional investors.

Health Catalyst Stock Down 2.9 %

Shares of Health Catalyst stock traded down $0.16 on Thursday, reaching $5.39. The company's stock had a trading volume of 456,933 shares, compared to its average volume of 774,837. The company has a market capitalization of $327.97 million, a price-to-earnings ratio of -3.99 and a beta of 1.34. The firm's fifty day simple moving average is $6.35 and its two-hundred day simple moving average is $7.31. Health Catalyst, Inc. has a 52 week low of $5.25 and a 52 week high of $9.72. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32.

Insiders Place Their Bets

In related news, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $5.76, for a total value of $30,003.84. Following the completion of the sale, the chief operating officer now owns 86,044 shares of the company's stock, valued at $495,613.44. The trade was a 5.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Linda Llewelyn sold 6,441 shares of Health Catalyst stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $5.43, for a total value of $34,974.63. Following the completion of the sale, the insider now directly owns 85,819 shares of the company's stock, valued at $465,997.17. The trade was a 6.98 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 87,610 shares of company stock valued at $664,043. Corporate insiders own 2.50% of the company's stock.

Wall Street Analysts Forecast Growth

HCAT has been the subject of several research analyst reports. Royal Bank of Canada dropped their price objective on Health Catalyst from $9.00 to $7.00 and set a "sector perform" rating for the company in a report on Wednesday, January 15th. Wells Fargo & Company lowered their target price on Health Catalyst from $13.00 to $10.00 and set an "overweight" rating for the company in a research note on Tuesday, January 21st. Canaccord Genuity Group lowered their target price on Health Catalyst from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Tuesday, January 21st. KeyCorp upgraded Health Catalyst from a "sector weight" rating to an "overweight" rating and set a $9.00 target price for the company in a research note on Wednesday, January 8th. Finally, Piper Sandler lowered their target price on Health Catalyst from $12.00 to $8.00 and set an "overweight" rating for the company in a research note on Tuesday, February 11th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Health Catalyst has a consensus rating of "Moderate Buy" and an average price target of $10.20.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.